SDPA Summer | Live Blog | Product Theater: Dupizent (dupilumab) Injection – The First Biologic for Adults with Uncontrolled Moderate-to-Severe Dermatitis
Sponsored by Regeneron/Sanofi Genzyme
During the lunch session at day 3 of SDPA’s Annual Summer Conference, Dr. Andrew Blauvelt presented an overview of the first FDA approved biologic treatment, Dupixent® (dupilumab) injection, for adults with uncontrolled moderate to severe atopic dermatitis. Atopic dermatitis (AD) is a common, chronic inflammatory skin disease associated with immune dysregulation and skin barrier dysfunction. It is estimated 1.6 million adults in the US suffer from uncontrolled moderate to severe atopic dermatitis.
In addition to symptom improvement, one of the main goals for treatment of atopic dermatitis is to control flares of the disease. Dr. Blauvelt explained that Dupixent® has a mechanism of action unlike any other treatment for atopic dermatitis through inhibition of IL-4 and IL- 13 signaling. Dupixent® can be used in combination with or without topical corticosteroids.
Furthermore, the most common side effects observed with use of Dupixent® include injection site reactions, eye and eyelid inflammation, including redness, swelling and itching, and cold sores in the mouth or on the lips. Symptoms of eye irritation may increase with the length of time that Dupixent® is used. This self-injected medication is dosed bi-weekly. No increase in systemic or skin infections has been observed in patients who have used Dupixent® for the treatment of their atopic dermatitis.
In summary, Dupixent® is a novel treatment for the moderate to severe atopic dermatitis patient for whom topical treatments have failed to control their disease.
Byline: Sarah Patton, PA-C, MSHS
Posted: June 3, 2017